ACTIBLOK-IPR

Products

Information

Biocon offers a wide range of metabolic which includes actiblok-ipr. Composition: metoprolol extended release 25/50/100mg tablets. Mechanism of action: metoprolol is a beta 1-selective (cardioselective) adrenergic receptor blocking agent. It competitively antagonizes catecholamines at peripheral (especially cardiac) adrenergic neuron sites, leading to decreased cardiac output. Indications: hypertension, angina/ihd, myocardial infarction in patients with hypertension, heart failure
Distribution Areas
North America (USA, Canada)East Asia (e.g. China, Japan, Korea)Europe - EU countriesEurope - non EU (e.g. UK, Russia, ex-CIS countries)South Asia (e.g. India, Pakistan, Sri Lanka)South East Asia (e.g. Thailand, Philippines, Singapore)
Supplied From
India
All categories
Drug Formulation (general category)Pharmaceutical Machinery & TechnologyProducts
Main Categories
Pharmaceutical Machinery & Technology
Biocon LimitedEstablished in 1978, Biocon Limited, is India's largest, and Asia's leading, biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide. We develop, manufacture and deliver a rich portfolio of Small Molecules APIs & Formulations and Complex Biologics - both Novels and Biosimilars - including MAbs, rh-insulin& Insulin Analogs. Biocon's robust product portfolio includes the world's first Pichia-based recombinant human Insulin, INSUGEN, Glargine, BASALOG and India's first biologic BioMAb-EGFR; for head and neck cancer. It has now successfully developed its second novel biologic Itolizumab, a 'first in class' anti-CD6 monoclonal antibody, being introduced as Alzumab; for psoriasis in India, in 2013.

Log in

See all the content and easy-to-use features by logging in or registering!